Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

February 1, 2014Open Access

Ver artículo completo

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment

HCHaiying ChengAlbert Einstein College of Medicine MSMarina ShcherbaMemorial Sloan Kettering Cancer Center GPGopichand PendurtiAlbert Einstein College of Medicine

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating resistance to EGF receptor tyrosine kinase inhibitors. Targeted agents against the components of this pathway are currently in development and their clinical benefits remain to be defined. This review provides an overview of the pathway dysregulation and novel agents targeting the pathway in lung cancer. In addition, potential predictive biomarkers guiding patient selection for targeted PI3K/AKT/mTOR inhibition is also discussed.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Cheng et al. (Sat,) studied this question.

synapsesocial.com/papers/69d99ff8e6ab964fb0836025 https://doi.org/https://doi.org/10.2217/lmt.13.72

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1SORAVE: Sorafenib and everolimus for treatment of patients with relapsed solid tumors and with KRAS mutated NSCLC—A phase I study.2013 · 2 citations
2BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study.2013 · 7 citations
3Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying <i>HER2</i>-activating mutations.2013 · 3 citations
4Chipping away at the lung cancer genome2012 · 191 citations
5A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500)2007 · 142 citations